Federal regulators on Thursday approved a new combination drug treatment for the most common form of cystic fibrosis. But it comes at a steep price—more than $250,000 for a year's treatment.
A proposed megamerger that would substantially consolidate hospitals' food-service supply chain is now on ice. Earlier this week, a federal judge issued a preliminary injunction halting Sysco Corp.'s planned acquisition of US Foods.
Safety net providers and clinics that participate in the 340B Drug Pricing Program will meet next month to address backlash from critics who feel the rising number of participants is a way to game the system during a period when drug prices are skyrocketing.
The Obama administration issued draft regulations that would impose fines on drug companies that overcharge hospitals and clinics for medication purchased under the government's 340B drug discount program.
Hill-Rom, a Chicago-based medical equipment manufacturer, announced it will acquire Welch Allyn, a Skaneateles Falls, N.Y.-based manufacturer of diagnostic and patient-monitoring equipment.
Strong clinical and operational performance at the nation's high-performing hospitals is associated with their more efficient use of drugs and supplies, according to a new study.
Cardinal Health announced Friday that it will acquire the Harvard Drug Group, a fellow pharmaceutical distributor, for about $1.1 billion. The medical-products distributor wants to strengthen its generic-drug business and expand its over-the-counter portfolio.
The CMS should evaluate the work of their Medicare administrative contractors to increase efficiency and improve quality, the GAO says in a new report.
Koch Industries, run by controversial conservative billionaires Charles and David Koch, has acquired Irish medical devicemaker Protek Medical through its subsidiary Molex, the company recently announced.
A federal appeals court ruled Friday that Actavis must continue to sell an Alzheimer's drug it wanted to pull off the market to limit competition from generics. It's a case with potential implications for pharmaceutical companies and patients nationwide, experts say.
Johnson & Johnson expects a lucrative return from its pharmaceutical business, with plans to seek approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.
Strong sales of Premier's software and a move into the direct-sourcing business led to double-digit revenue growth in the third quarter, but increased costs and investment losses led to a sharp decrease in profit.